https://twitter.com/LifeOnADT
Read MoreDoes intermittent ADT (IADT) have lower risk of serious side effects than continuous ADT (CADT)?
Key sentence from the paper: “…the IADT group showed consistent reduced risk of these serious toxicities compared to the CADT group in both subgroups with or without comorbidities...”
Read MoreDoes ADT reduce the need to wake up at night to pee?
Key sentence from the paper: “In contrast to patients with moderate to severe [lower urinary tract symptoms], nocturia showed a significant increase during ADT therapy in patients with mild symptoms.”
Read MoreWhat’s the latest on ADT research?
Key sentence from the paper: “All clinical trials of newer agents… in [metastatic castrate-resistant prostate cancer] include patients who maintain castrate levels of testosterone, and so clinical practice should adhere to this principle of continuing ADT when initiating abiraterone, enzalutamide or chemotherapy.”
Read MoreDoes ADT increase the risk of pneumonia?
Key sentence from the paper: "The use of ADT is associated with an increased risk of hospitalisation for community-acquired pneumonia in men with prostate cancer.”
Read MoreDoes surgery or radiotherapy carry an increased risk of cardiovascular disease and bone fractures (independent of ADT)?
Key sentence from the paper: “… treatments with radiotherapy…and ADT…were each independently associated with increased risk of coronary heart disease, sudden cardiac death, fracture, and fracture requiring hospitalization.”
Read MoreDoes ADT cause dementia?
Key sentence from the paper: “Our study extends previous work supporting an association between use of ADT and Alzheimer disease and suggests that ADT may more broadly affect neurocognitive function.”
Read MoreDoes the benefit of ADT vary depending on comorbidities and other risk factors one has?
Key sentence from the paper: “The risk of [prostate cancer specific mortality] significantly decreased with the addition of ADT in the setting of high-dose [radiation therapy] for men with intermediate- or high-risk [prostate cancer] with a low, but not a high [competing mortality] score.”
Read MoreIs free testosterone better than total testosterone for indicating prostate cancer progression?
Key sentence from the paper: “The role of serum [total testosterone] measurement during ADT remains unclear and here we have generated the hypothesis that [free testosterone] determination at 6-month is a better surrogate than [total testosterone] to predict [castrate-resistant prostate cancer] in patients with no metastatic disease.”
Read MoreDoes one’s testosterone level, when starting ADT, have any effect on their long-term survival?
Key sentence from the paper: “…in men with known [coronary artery disease], only those with baseline low and lower 1/3 of the normal testosterone had a significantly higher [overall mortality] when they received ADT >6months compared with when they did not.”
Read More